20 March 2024
BSF Enterprise PLC
("BSF" or the "Company")
Result of Annual General Meeting
BSF Enterprise (LSE: BSFA), (OTCQB: BSFAF), the Main Market listed biotech company and owner of pioneering UK-based tissue engineering company 3D Bio-Tissues Ltd (3DBT) and corneal tissue replacement company Kerato Ltd, is pleased to announce that at the Company's Annual General Meeting held earlier today, all resolutions proposed were duly passed by shareholders by way of a poll, the results of which were as follows:
| Resolution | Poll Results | |||||
| For | Against | Withheld | Discretionary | Total | ||
| 1 | Shares | 52,426,227 | - | - | - | 52,426,227 |
| % | 100.00% | - | - | - | 100% | |
| 2 | Shares | 52,421,227 | 5,000 | - | - | 52,426,227 |
| % | 99.99% | 0.01% | - | - | 100% | |
| 3 | Shares | 52,421,227 | 5,000 | - | - | 52,426,227 |
| % | 99.99% | 0.01% | - | - | 100% | |
| 4 | Shares | 52,426,227 | - | - | - | 52,426,227 |
| % | 100.00% | - | | - | 100% | |
| 5 | Shares | 46,646,377 | - | 5,779,850 | - | 52,426,227 |
| % | 88.98% | - | 11.02% | - | 100% | |
| 6 | Shares | 52,426,227 | - | - | - | 52,426,227 |
| % | 100.00% | - | - | - | 100% | |
| 7 | Shares | 52,402,826 | 23,401 | - | - | 52,426,227 |
| % | 99.96% | 0.04% | - | - | 100% | |
| 8 | Shares | 52,421,227 | - | 5,000 | - | 52,426,227 |
| % | 99.99% | - | 0.01% | | 100% | |
| 9 | Shares | 52,397,826 | 23,401 | 5,000 | - | 52,426,227 |
| % | 99.95% | 0.04% | 0.01% | - | 100% | |
About BSF Enterprise PLC:
BSF Enterprise PLC (BSF) is focused on unlocking the next generation of biotechnological solutions - using cellbased tissue engineering to help generate cultured meat, lab-grown leather, as well as human corneas, collagen growth and skin substitutes, as part of a radical transformation to deliver sustainable solutions across a variety of sectors.
It owns 100% of 3D Bio-Tissues (3DBT), a tissue engineering with patent-protected IP that is already producing human corneas for testing to help restore vision to millions of people. Building on this success, it aims to produce the UK's first high quality leather from its laboratory in Newcastle, transforming the leather industry towards an ethical and sustainable practice.
BSF aims to deliver growth to shareholders through the continued commercialisation of 3DBT's IP, which has multiple applications, as well as through M&A. It aims to develop a suite of technologies that underpins the development of tissue templating for corneas, meat and leather, and license out the IP to manufacturers, wholesalers and distributors to help manufacture the products at scale.
For further enquiries, please visit www.bsfenterprise.com or contact:
| BSF Enterprise PLC | Via SEC Newgate below |
| Geoff Baker - Executive Director Che Connon - CEO & Director
| |
| Shard Capital (Broker) | |
| Damon Heath | 0207 186 9000 0207 186 9927
|
| SEC Newgate (Financial Communications) | |
| Bob Huxford | 020 3757 6882 |
| Elisabeth Cowell | BSF@secnewgate.co.uk |
ISIN of the Ordinary Shares is GB00BHNBDQ51
SEDOL Code is BHNBDQ5.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.